Veterinary Medicines

Bovilis IBR marker Live

Authorised
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
Download as PDF

Product identification

Medicine name:
Bovilis IBR marker Live
BOVILIS IBR MARKER LIVE
Active substance:
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
Target species:
  • Cattle
Route of administration:
  • Nasal use
  • Intramuscular use

Product details

Active substance and strength:
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
    5.70
    log10 50% tissue culture infectious dose
    /
    2.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate for suspension for injection
Withdrawal period by route of administration:
  • Nasal use
    • Cattle
      • Milk
        no withdrawal period
      • Meat and offal
        no withdrawal period
  • Intramuscular use
    • Cattle
      • Milk
        no withdrawal period
      • Meat and offal
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AD01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Italy
Available in:
  • Italy
Package description:
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (100 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (200 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (10 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (20 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (100 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 PET vials of solvent (100 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (5 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (10 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (25 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (50 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 glass vial (hydrolytic type II) of solvent (100 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 PET vial of solvent (100 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (5 doses) and 1 glass vial (hydrolytic type II) of solvent (10 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (25 doses) and 1 glass vial (hydrolytic type II) of solvent (50 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (100 doses) and 1 glass vial (hydrolytic type II) of solvent (200 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (10 doses) and 1 glass vial (hydrolytic type II) of solvent (20 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • Ministry Of Health
Authorisation number:
  • 103321
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0105/001
Concerned member states:
  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 22/07/2024
Download